Phase II Trial of Ixabepilone Administered Daily for Five Days in Children and Young Adults with Refractory Solid Tumors: A Report from the Children’s Oncology Group

PURPOSE: Ixabepilone is a microtubule-stabilizing agent with activity in adult solid tumors and in pediatric tumor xenograft models that are resistant to paclitaxel. The maximum tolerated dose on the daily × 5 d intravenous schedule was 6 mg/m(2)/dose in adults and 8 mg/m(2)/dose in children, and th...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Jacobs, Shana, Fox, Elizabeth, Krailo, Mark, Hartley, Gwen, Navid, Fariba, Wexler, Leonard, Blaney, Susan M., Goodwin, Anne, Goodspeed, Wendy, Balis, Frank M., Adamson, Peter C., Widemann, Brigitte C.
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3086796/
https://ncbi.nlm.nih.gov/pubmed/20068084
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-09-1906
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars